Clinical trial · Observational
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
NCT04724031CI-TRIAL-00064685unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PARP inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- One cohort
- description
- women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment
- interventionNames
- Drug: PARP inhibitor
Primary outcomes (1)
- measure
- Evaluation of Progression Free Survival
- timeFrame
- 12/2022
Secondary outcomes (2)
- measure
- Assessment of the safety profile of olaparib in women with advanced high grade ovarian cancer
- timeFrame
- 12/2021
- measure
- Assessment of the safety profile of niraparib in women with advanced high grade ovarian cancer
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: \- women \>18 years old with advanced high grade ovarian cancer Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.